Newron Pharmaceuticals SpA (NWPHF)

OTHER OTC:NWPHF

NWPHF

Newron Pharmaceuticals SpA

RESEARCH TOOLSreports

Want to see NWPHF full AI Analyst Report?

Newron Pharmaceuticals SpA (NWPHF) Price & Analysis

12 Followers

NWPHF Stock Chart & Stats

$20.00

$0.00(0.00%)

At close: Sep 09 4:00 PM EDT

$20.00

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$9.36 - $20.00

Previous CloseN/A

Volume30.00

Average Volume (3M)0.00

Market Cap

$451.64M

Enterprise Value$408.47M

Total Cash (Recent Filing)$28.85M

Total Debt (Recent Filing)$38.13M

Price to Earnings (P/E)―

Beta0.85

Next Earnings

Sep 22, 2026

EPS Estimate

-0.87

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding20,805,798

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)-45.95

Price to Sales (P/S)26.73

P/FCF Ratio15.73

Enterprise Value/Market Cap0.90

Enterprise Value/Revenue21.34

Enterprise Value/Gross Profit21.36

Enterprise Value/Ebitda285.64

Forecast

1Y Price Target

$61.44

Price Target Upside207.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.46

Revenue Forecast (FY)$49.36M

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentA global pivotal program with two Phase 3 studies offers multiple potential value inflection points if the trials demonstrate favorable efficacy, tolerability, and safety.

Intellectual PropertyA newly granted composition-of-matter patent and completion of national patent filings in key countries strengthen global patent protection and help delay generic competition.

Regulatory PathwayInitiation of a U.S. pivotal study along with regulatory and ethics approvals supports a clear pathway toward a U.S. regulatory submission if trial outcomes meet requirements.

Bears Say

Enrollment RiskTrial readout timing depends on patient enrollment pace, and slower enrollment could delay potential regulatory submission timelines and postpone expected value realization.

Market ConcentrationHeavy reliance on success in U.S. and European markets concentrates commercial risk, so underperformance in those regions would significantly reduce the drug's projected value.

Newron Pharmaceuticals SpA News

Newron Pharma price target raised to CHF 48 from CHF 43 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 48 from...

23d ago

Newron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead

Newron Pharmaceuticals SpA (($CH:NWRN)) has held its Q4 earnings call. Read on for the main highlights of the...

21d ago

Newron bolsters finances as Evenamide enters pivotal global Phase III

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an announcement. Newron Pharmaceuticals reported a transformative 2025 marked by...

24d ago

Newron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an update. Newron reported 2025 as a landmark year, driven...

24d ago

Newron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an update. Newron Pharmaceuticals will showcase new data on its...

28d ago

Newron extends EIB loan maturities to align financing with Evenamide milestones

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an update. Newron Pharmaceuticals has reached an agreement in principle...

29d ago

Newron refreshes board with CNS and capital markets experts ahead of AGM

An announcement from Newron Pharmaceuticals SpA ( ($CH:NWRN) ) is now available. Newron Pharmaceuticals announced upcoming changes to...

1M ago

Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an update. Newron Pharmaceuticals has secured commitments of up to...

2M ago

Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has shared an announcement. Newron Pharmaceuticals has secured an equity financing package...

2M ago

Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an announcement. Newron Pharmaceuticals has highlighted a new peer-reviewed publication...

2M ago

Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 43 from...

3M ago

EA Pharma Starts Phase III Trial of Newron’s Evenamide for Treatment‑Resistant Schizophrenia in Japan

The latest announcement is out from Newron Pharmaceuticals SpA ( ($CH:NWRN) ). Newron Pharmaceuticals’ partner EA Pharma, a...

3M ago

Newron Pharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 73...

4M ago

Newron Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 26 price target The...

4M ago

NWPHF FAQ

What was Newron Pharmaceuticals SpA’s price range in the past 12 months?

Newron Pharmaceuticals SpA lowest stock price was $9.36 and its highest was $20.00 in the past 12 months.

What is Newron Pharmaceuticals SpA’s market cap?

Newron Pharmaceuticals SpA’s market cap is $451.64M.

When is Newron Pharmaceuticals SpA’s upcoming earnings report date?

Newron Pharmaceuticals SpA’s upcoming earnings report date is Sep 22, 2026 which is in 158 days.

How were Newron Pharmaceuticals SpA’s earnings last quarter?

Newron Pharmaceuticals SpA released its earnings results on Mar 24, 2026. The company reported -$0.763 earnings per share for the quarter, missing the consensus estimate of -$0.092 by -$0.67.

Is Newron Pharmaceuticals SpA overvalued?

According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA does not currently pay dividends.

What is Newron Pharmaceuticals SpA’s EPS estimate?

Newron Pharmaceuticals SpA’s EPS estimate is -0.87.

How many shares outstanding does Newron Pharmaceuticals SpA have?

Newron Pharmaceuticals SpA has 20,805,798 shares outstanding.

What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?

Newron Pharmaceuticals SpA reported an EPS of -$0.763 in its last earnings report, missing expectations of -$0.092. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?

Currently, no hedge funds are holding shares in NWPHF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Newron Pharmaceuticals SpA

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Newron Pharmaceuticals SpA (NWPHF) Earnings & Revenues

Historic Earnings Reports

NWPHF Stock 12 Month Forecast

Average Price Target

$61.44

▲(207.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","62":"$62","20.75":"$20.8","34.5":"$34.5","48.25":"$48.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61.436016,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$61.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.436016,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.44</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,20.75,34.5,48.25,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.36,13.365847384615385,17.37169476923077,21.377542153846154,25.38338953846154,29.389236923076925,33.39508430769231,37.400931692307694,41.40677907692308,45.412626461538466,49.41847384615385,53.42432123076924,57.430168615384616,{"y":61.436016,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.36,13.366153846153846,17.372307692307693,21.378461538461536,25.384615384615383,29.39076923076923,33.39692307692307,37.403076923076924,41.40923076923077,45.41538461538461,49.42153846153846,53.427692307692304,57.43384615384615,{"y":61.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.36,13.365847384615385,17.37169476923077,21.377542153846154,25.38338953846154,29.389236923076925,33.39508430769231,37.400931692307694,41.40677907692308,45.412626461538466,49.41847384615385,53.42432123076924,57.430168615384616,{"y":61.436016,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.52,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >